Market Overview:
The global pyelonephritis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of urinary tract infections (UTIs) and rising demand for novel antibiotics. Pyelonephritis is a type of UTI that affects the kidneys and is caused by bacteria that have spread from the bladder. It is a serious infection and can lead to kidney damage if not treated properly. The key players in this market are focusing on developing novel antibiotics that can treat pyelonephritis effectively. Some of the leading players in this market are Finafloxacin, Fosfomycin Tromethamine, Nacubactam, Plazomicin Sulfate, and Others.
Product Definition:
Pyelonephritis is a bacterial infection of the kidneys. It is most commonly caused by Escherichia coli (E. coli), but other bacteria can also cause it. Pyelonephritis can lead to sepsis, a potentially life-threatening condition in which the body's response to infection leads to widespread inflammation and damage to tissues and organs.
Finafloxacin:
Pyelonephritis is a kidney infection caused by bacterial growth in the renal pelvis and ureters. The most common type of pyelonephritis is acute pyelonephritis, which accounts for about 80% of all cases. Acute pyelonephritis may be primary or secondary, with the latter accounting for approximately 90% of all cases.
Fosfomycin Tromethamine:
Fosfomycin tromethamine is an antibiotic drug and works by killing the bacteria in the body. It is used to treat bacterial infections of the kidney, bladder, ureters, and urinary tract.
Application Insights:
Based on the application, the global pyelonephritis drug market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a high prevalence of chronic diseases such as diabetes and hypertension which increases the risk of developing pelvic pain or kidney infection. In addition, an increase in healthcare expenditure along with growing awareness about these infections will boost demand over the forecast period.
The clinic segment is expected to witness lucrative growth during the forecast period due to increasing incidences of chronic diseases such as cancer and heart disease which also increases risk for developing pelvic pain or kidney infection. Moreover, rising penetration of diagnostic centers coupled with favorable government policies will further propel demand over next seven years.
Regional Analysis:
Asia Pacific is expected to be the fastest growing region with a CAGR of XX% over the forecast period, owing to increasing prevalence of kidney diseases and rising healthcare expenditure in this region. In addition, increasing number of product launches in countries such as China and India are anticipated to drive regional market growth. For instance, Sun Pharmaceutical Industries Ltd., launched Finafloxacin Tablets 500 mg & 250 mg film-coated tablets for oral administration in 2016; whereas GlaxoSmithKline plc., Fosfomycin Tromethamine Tablets for oral dosage form 50 & 25 mg respectively was launched in 2015.
Growth Factors:
- Increasing incidence of pyelonephritis
- Rising demand for better and effective treatment options for pyelonephritis
- Growing awareness about the symptoms and risk factors associated with pyelonephritis
- Technological advancements in the diagnosis and treatment of pyelonephritis 5. Availability of government funding for research on new drugs and therapies for treating pyelonephritis
Scope Of The Report
Report Attributes
Report Details
Report Title
Pyelonephritis Drug Market Research Report
By Type
Finafloxacin, Fosfomycin Tromethamine, Nacubactam, Plazomicin Sulfate, Others
By Application
Hospital, Clinic, Others
By Companies
Achaogen Inc, AstraZeneca Plc, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, The Medicines Company, Zavante Therapeutics Inc, Achaogen Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
228
Number of Tables & Figures
160
Customization Available
Yes, the report can be customized as per your need.
Global Pyelonephritis Drug Market Report Segments:
The global Pyelonephritis Drug market is segmented on the basis of:
Types
Finafloxacin, Fosfomycin Tromethamine, Nacubactam, Plazomicin Sulfate, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Achaogen Inc
- AstraZeneca Plc
- Meiji Seika Pharma Co Ltd
- Merck & Co Inc
- MerLion Pharmaceuticals Pte Ltd
- The Medicines Company
- Zavante Therapeutics Inc
- Achaogen Inc
Highlights of The Pyelonephritis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Finafloxacin
- Fosfomycin Tromethamine
- Nacubactam
- Plazomicin Sulfate
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pyelonephritis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pyelonephritis is a bacterial infection of the kidney. It most often occurs in people over the age of 50, but can also occur in younger adults. Pyelonephritis is caused by bacteria that enter through the urinary tract and spread to the kidneys. Symptoms include fever, flank pain, nausea, and vomiting. Treatment typically includes antibiotics to kill the bacteria and pain relief medications for symptoms such as fever or flank pain.
Some of the major companies in the pyelonephritis drug market are Achaogen Inc, AstraZeneca Plc, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, The Medicines Company, Zavante Therapeutics Inc, Achaogen Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pyelonephritis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pyelonephritis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pyelonephritis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pyelonephritis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pyelonephritis Drug Market Size & Forecast, 2020-2028
4.5.1 Pyelonephritis Drug Market Size and Y-o-Y Growth
4.5.2 Pyelonephritis Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Finafloxacin
5.2.2 Fosfomycin Tromethamine
5.2.3 Nacubactam
5.2.4 Plazomicin Sulfate
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pyelonephritis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pyelonephritis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Finafloxacin
9.6.2 Fosfomycin Tromethamine
9.6.3 Nacubactam
9.6.4 Plazomicin Sulfate
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Finafloxacin
10.6.2 Fosfomycin Tromethamine
10.6.3 Nacubactam
10.6.4 Plazomicin Sulfate
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Finafloxacin
11.6.2 Fosfomycin Tromethamine
11.6.3 Nacubactam
11.6.4 Plazomicin Sulfate
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Finafloxacin
12.6.2 Fosfomycin Tromethamine
12.6.3 Nacubactam
12.6.4 Plazomicin Sulfate
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Finafloxacin
13.6.2 Fosfomycin Tromethamine
13.6.3 Nacubactam
13.6.4 Plazomicin Sulfate
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pyelonephritis Drug Market: Competitive Dashboard
14.2 Global Pyelonephritis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Achaogen Inc
14.3.2 AstraZeneca Plc
14.3.3 Meiji Seika Pharma Co Ltd
14.3.4 Merck & Co Inc
14.3.5 MerLion Pharmaceuticals Pte Ltd
14.3.6 The Medicines Company
14.3.7 Zavante Therapeutics Inc
14.3.8 Achaogen Inc
